The New Immunotherapy for Cancer: What You Need to Know
|
|
- August Parrish
- 8 years ago
- Views:
Transcription
1 The New Immunotherapy for Cancer: What You Need to Know Barbara E. Kitchell, DVM, Ph.D., DACVIM VCA Veterinary Care Animal Hospital and Referral Center Albuquerque, NM The immune system is a miraculous and wonderful thing, capable of protecting us from many of life's little (or big) annoyances such as viral and bacterial diseases. Any foreign agent that can be recognized by the immune system is antigenic, and if the immune system can mount an active response against the foreign agent, it is immunogenic. Not all antigens are immunogenic, and herein lies the difficulty of cancer immunotherapy. Many investigators believe that the immune system has a major function in immune surveillance against cancer development. In the view of these investigators, the patient who develops overt malignancy has suffered an immune system failure. tii s true that a large body of evidence has been amassed over the years demonstrating that manipulation of the immune response can lead to tumor regression and occasionally to cure. Most of this work has been performed with rodents bearing transplantable tumors, where the antigenic difference between the tumor and host cells is large. Unfortunately, there is less compelling evidence for the reliable therapeutic benefits of the immune system in spontaneous animal and human malignancies. In order for the immune system to kill cancer cells, target molecules must be present that are immunogenic. These target molecules should be specific to the tumor in order for a differential response to be mounted against it. The presence of tumor associated antigens (TAA) is supported by research in rodents with transplantable, virally induced and chemically induced tumor models. In the case of long established transplantable tumors in rodents, the immune system is capable of eradicating modest tumor burdens, and the treated animal is protected against later challenge with the same tumor cells. Unfortunately, it is thought that although the transplantable tumors were originally syngeneic with the host mice into which they are implanted, over the course of many cell culture and animal passages, the cells experience genetic drift, or mutations which allow the immune system to "see" them. Tumors that are induced in rodents by viruses or high doses of carcinogens are usually highly immunogenic, but chronic low dose administration of carcinogens (the most likely model for human and spontaneous animal tumor development) produces tumors that are weakly immunogenic at best. In short, cancers that arise in an individual should not trigger the immune system; they are not foreign in origin and thus are tolerated, at least above a certain threshold of cell dose. If immune surveillance is useful to the body, it is in scavenging out micrometastatic disease
2 or very tiny early malignancies. Immunotherapy - There are several approaches to immunotherapy that have been tried. They are characterized as active, passive, specific and non-specific. In the case of active immunotherapy, attempts are made to stimulate the immune response of the host by "firing up" the immune system by nonspecific means such as injections of BCG, or newer analogs like Immunocidin, or by specific means such as injections of killed, modified tumor cells (autologous vaccine approach). Passive immunity refers to the transfer of immune effectors (cells or antibodies) from an immunized individual into the cancer-bearing patient. Examples of these approaches include serotherapy (injection of immune serum for immunized animals), monoclonal antibody injections, or adoptive immunotherapy with injection of effector cells (tumor infiltrating lymphocytes, lymphokine activated killer cells, or natural killer cells) from immunized animals. Newer non-specific active immune approaches include the injection of recombinant proteins that act as biologic response modifiers such as Interleukin-2, Tumor Necrosis Factor, and Interferons to stimulate an immune response. Overcoming immune tolerance of cancer is a highly desirable yet major challenge to effective cancer therapy. Numerous strategies have been proposed with the common goal of stimulating cell-mediated immune responses to cancer. Cell-mediated immunity may benefit cancer patients in several ways including the generation of tumor reactive lymphocytes capable of killing cancer cells, systemic circulation of tumoricidal lymphocytes with the capacity to kill metastatic foci, potent killer immune cells able to destroy chemotherapy-resistant tumor cells, and the development of long-term endogenous tumor surveillance through the generation of tumor-specific memory T cells. Head and neck cancer, and canine oral melanoma in particular, has become the "testing ground" to explore and develop some strategies for immunotherapy. With a few exceptions in veterinary medicine, at this time all efforts to harness the immune system It combat cancer remain investigational and there are few biological response modifiers that are routinely available in private practice. One notable exception to this statement is the xenogeneic melanoma vaccine (Oncept) from Merial, which is advancing the field of veterinary immunotherapy and helping patients live longer, healthier lives, at least in theory. More recently, a mycobacterial cell wall fraction has been commercialized for treatment of mixed mammary tumors and mammary adenocarcinoma in dogs, (Immunocidin). It may be premature to consider immunotherapy as the "best way" to treat cancer now, but the intense research, novel approaches, and achievements to date herald a bright and promising future for this discipline. Immunotherapy for melanoma - Long-term survival of dogs with advanced malignant melanoma was achieved after DNA vaccination with xenogeneic human tyrosinase antigen, available under limited license in the United States from Merial (Oncept ). This xenogeneic vaccine contains human DNA for the gene tyrosinase, which is highly expressed in melanocytes as part of the production of melanin pigment. The gene is under the control of a strong cytomegalovirus (CMV) promoter, which results in production of the human protein in canine muscle. The vaccine is introduced to muscle by use of a needle-less bioinjector system. Once the dog begins to produce the human
3 protein, the canine immune system recognizes the human tyrosinase enzyme and is hopefully sufficiently potent to break self-tolerance to eradicate remaining microscopic (or in some cases even macroscopic) melanoma tumor burden in the dog. The vaccine is administered on an every other week basis for 4 treatments, then as booster injections every 6 months. Responses have been seen even in dogs with transient tumor progression. Optimally, dogs should have the tumor burden reduced to T0 (microscopic) by surgery and/or radiation therapy prior to vaccination. In the phase one trial, median survival for 9 dogs treated was 389 days, with complete responses reported and greater that 588-day survival for one dog with bulky non-resectable disease. Dogs that demonstrated antigen specific antibody responses were more likely to have positive responses clinically. Expanded trials have been reported in abstract form but limited peer-reviewed publications are available for evaluation. However, these expanded trials were sufficient to result in full licensure of the product by the FDA in Other immune approaches under study for canine oral melanoma include treatment with allogeneic and autologous tumor cell vaccines, gene therapy, cytokines, and antibodies. The rationale for tumor cell vaccines is based on the idea that attenuated transfected tumor cells may serve as an antigen source and a vehicle to deliver immunostimulatory cytokines concurrently. Following surgery to remove all gross melanoma, the gene for GM-CSF is transfected into the dog's own tumor cells (autologous) or canine melanoma cells from an established cell line (allogeneic) and these cells are injected repeatedly to induce antitumor immunity. It is a well-tolerated, easily administered treatment making it attractive for the practice setting. Intratumoral injection of immunostimulatory genes (e.g., interleukin-2, staphylococcal enterotoxin B) is another strategy that relies on melanoma cells to secrete immunostimulatory molecules and has also demonstrated clinical activity. Intratumoral injection of genes that promote apoptosis (e.g., Fas ligand, p21, etc.) to increase the availability of tumor antigen for immune cell processing and presentation, are under study as well. Systemic administration of interleukin-2 (IL-2) also has been shown to activate the immune system of dogs with advanced oral melanoma, and anti melanoma monoclonal antibodies (e.g., antiganglioside G02, G03) have been combined with IL-2 to promote trafficking of immune cells to tumor targets. COX-2 and Cancer-After cellular injury, lipids are released from plasma membranes and metabolized into mediators capable of changing cellular physiology. Since these lipids are present at the first site exposed to the injury, they provide an ideal substrate for the synthesis of defensive mediators and homeostatic regulators. One such group of lipid mediators is the prostanoids, including PGs and thromboxanes (TXs). Prostanoids were initially categorized as proinflammatory, but as the understanding of prostanoid physiology has evolved, it has become clear that these substances can act to both promote and inhibit inflammation. Prostanoid production depends on the activity of the two COX isoenzymes. COX-l is present in most cells and its expression is generally constitutive. In contrast, COX-2 is found in the brain and kidneys where in other organs its expression is low or undetectable, until stimulation takes place when its activity dramatically increases. Increased expression of COX-1 upon stimulation also can occur
4 and has been found in mast cells, macrophages and dendritic cells, in certain inflammatory responses, at the first 30 minutes after stimulation. In the same way, COX- 2 can be upregulated in special physiologic situations such as in the ovaries during ovulation and pregnancy. PGH2 is produced by both COX isoforms and is the common substrate for a series of specific synthase enzymes that produce PGD2, PGE2, PGF2- alpha, PGI2 and TXA2. In the cancer scenario, COX-2 overexpression has been associated with numerous carcinomas (eg: colon, gastric, esophageal, breast, pancreatic) as well as some sarcomas and melanoma. COX-2 effects on cell cycle have been associated with increased angiogenesis, increased cell growth, resistance to apoptosis, decreased adhesiveness, resistance to chemotherapy, and increased invasiveness. COX-2 overexpression has been associated with aggressiveness in colon, lung, SCCHN, and breast cancers. In breast cancer patients, strong association was found between expression of COX-2 and MDRl/Pgp-170 and consequently, resistance to chemotherapy. The theory that prostaglandins and NSAIDs can affect carcinogenesis arose from the relationship between chronic inflammation and cancer. Ulcerative colitis, eosinophilic cystitis, pelvic inflammatory disease, and systemic lupus erythematosis in humans, have all been associated with increased risk for malignancies. In support of this concept, studies have shown that colonic adenomatous polyps and colon cancer, can be prevented in up to 50% among patients who took aspirin for more than four years. Similar results have recently been obtained in trials that access prevention of breast cancer. Optimal frequency of administration and dose are unknown, but one study demonstrated that with infrequent aspirin use (less than once a month), the relative risk of death due to colon cancer were 0.77 for men and 0.73 for women; this risk decreased further to 0.60 for men and 0.58 for women if aspirin was taken more than 16 times per month. In dogs, overexpression of COX-2 has been observed in transitional cell carcinoma of the bladder and squamous cell carcinoma. In general NSAIDs will act on tumors by COX-2 dependent as well as COX-2 independent mechanisms. Piroxicam, a COX-nonspecific NSAID, is widely accepted as a treatment for canine transitional cell carcinoma (TCC). Mechanistically, benefits from piroxicam are attributed primarily to its ability to block COX2 activity in the cancer cells. COX2 has been associated with immunosuppressive effects of prostaglandins (e.g., PGE2) and there is growing interest in the use of COX2 inhibitors to treat human cancer. Although response rates are low, the observation that TCC responds to piroxicam at all implies canine bladder cancer is not an immunologically privileged site and may be an interesting tumor for other immune interventions. Cox-2 inhibition may also work through anti-angiogenic means as well. Metronomic chemotherapy as an anticancer strategy Targeting of chemotherapeutic agents or other substances that may inhibit endothelial cell growth (e.g., vascular endothelial growth factor receptor therapy) represent promising strategies for cancer treatment. Low dose continuous chemotherapy has the capacity to not only affect cancer cells themselves, but also to normalize a suppressed immune response. Recent studies by Dr. Barb Biller of Colorado State University
5 indicate that low doses of cyclophosphamide (ie 15 mg/m2 PO daily as reformulated capsules) can re-balance the immune system by decreasing levels of regulatory T lymphocytes (T-regs), which act as suppressor T s. In dogs with high levels of CD8 cytotoxic T lymphocytes compared to T-regs, survival and disease free interval was statistically prolonged in canine osteosarcoma patients when compared to dogs with a decreased CD8/T-reg ratio. Thus, people have begun using metronomic combination chemotherapy using a NSAID drug such as piroxicam, daracoxib, or meloxicam, along with continuous low dose cyclophosphamide by mouth. Some protocols are supplemented with other potentially therapeutic agents such as toceranib, which is a VEGFR2 inhibitor, or doxycycline. These studies are ongoing, but the impact of this approach is also being promoted because of the potential for cost-effective anticancer therapy. Non-Specific Active Immunotherapy There has been a long series of studies investigating agents that activate various components of the immune system as anticancer strategies. Dr. Greg MacEwen was a champion of the dog model for bacterial cell wall containing agents such as liposome encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE). This agent was found to prolong disease free interval and survival in dogs suffering osteosarcoma, and subsequently in children with the same disease, leading to the licensure of this compound in Europe to treat pediatric osteosarcoma (Mifamurtide- Ciba Geigy). A trial with this nonspecific macrophage activator also extended the survival of dogs with splenic hemangiosarcoma (in combination with surgery and doxorubicin/cyclophosphamide), but thus far this agent is not available for veterinary clinical practice. However, a recently licensure was granted for a different Mycobacterial cell wall fraction agent (Immunocidin - Bioniche) which is indicated for use in dogs with mammary tumors. Immunocidin is administered only by intratumoral injection. The entire tumor and a small region of adjacent and underlying tissue are infiltrated using a 20-gauge needle. Injection must be carefully applied to insure full coverage of the tumor bed or treatment may be ineffective. The drug is in an emulsion that must be thoroughly mixed prior to injection, with injection as quickly as possible because the emulsion may begin to separate soon after mixing. The tumor tissue may be very firm and excessive pressure on the syringe plunger may be required to infiltrate the tumor. The injection may produce local pain so use of anesthetics or additional analgesics may necessary. Dosage varies with tumor size but 1 ml should be considered a minimum dose. Treatment may be given once, followed by surgical excision of tumor in 2-4 weeks. The agent is reported to be well tolerated by aged dogs with chronic cardiovascular and renal disease, and may occasionally result in tumor regression in debilitated patients even without surgery for those patients who are poor surgical risks. In this scenario, treatment is repeated every 1-3 weeks, and tumors that fail to respond after 4 treatments should be considered refractory and therapy discontinued. According to the manufacturer s information, eighty-eight percent of dogs treated with immunotherapy only were free of tumor two years later. Individual doses range from 1 to 30 ml (average about 2.5 ml). The average cumulative dose is about 10 ml. Lymphoma immunotherapy Despite great advances with chemotherapy in the treatment of canine malignant
6 lymphoma, the majority of affected dogs develop chemoresistance and die of this disease. A number of strategies are under consideration to circumvent this resistance that are intended to stimulate antitumor immune responses. These include (but are not limited to) targeting lymphoma antigens with unmodified ("naked") antibodies or antibodies armed with toxins or isotopes, targeting growth factor receptors on lymphoma cells with armed growth factors, lymphoma idiotype vaccines, and whole tumor cell vaccines. An antibody that binds to CD20 on the surface of human B cells (Rituximab ) is now an approved treatment for some forms of human lymphoma. After binding to the target cells, the antibody triggers tumor cell killing through antibody-dependent cell mediated and complement-dependent cytotoxic mechanisms. Unfortunately, this antibody has proven ineffective in binding the target CD20 antigen in veterinary species. However, several companies are engaged in production of canine-specific monoclonal antibodies that may meet this need in the future. A CD19 antigen targeted monoclonal antibody is in trials currently for canine B-cell lymphoma. Targeted immunotherapy The interleukin-2 receptor (IL-2R), normally found on activated lymphocytes, has been identified on the malignant lymphocytes from a number of forms of human lymphoma. In this setting, IL-2R is expressed inappropriately, representing a tumor-associated antigen and not normal expression of an activation molecule. This receptor, composed of three distinct subunits (a, b, g), has been intensively studied as a target for cancer immunotherapy. In human oncology, an antibody against the IL-2Ra subunit has been developed and used either unmodified, armed with a bacterial toxin, or armed with an isotope for the treatment of IL-2R+ human lymphomas. Because this antibody does not recognize IL-2Ra on canine lymphoid cells, an antibody specific for canine IL-2Ra is under development. The majority of canine lymphomas do express IL-2Ra (as well as IL-2Rb and g), suggesting that strategies targeting this receptor in canine lymphoma may have wide applicability. Another approach targeting the IL-2R in lymphoma relies on the ability of this receptor to bind IL-2, the ligand for IL-2R. Thus, an IL-2R-toxin fusion molecule has been licensed for some forms of human lymphoma. The therapy relies on IL-2 to target a toxin directly to IL-2R+ cancer cells. This fusion protein, commercially available as Ontak, is composed of IL-2 bound to diphtheria toxin and it only takes one molecule to kill a tumor cell. Further, because of its unique mechanism of action, chemotherapy resistance is overcome. Several dogs with lymphoma have received Ontak, to our knowledge, without showing conclusive proof of efficacy. The IL-2R status of these dogs' lymphoma cells is unclear and expression of IL-2R is a prerequisite for the rational use of Ontak. More dogs will likely be treated with this molecule in the future although it may be cost prohibitive for many pet owners.
Osteosarcoma: treatment beyond surgery
Osteosarcoma: treatment beyond surgery Eric Chow, DVM DACVS Sue Downing, DVM DACVIM-Oncology Providing the best quality care and service for the patient, the client, and the referring veterinarian. Osteosarcoma
More information1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT
1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT Learning that your pet has a diagnosis of cancer can be overwhelming. We realize that your pet
More informationspecific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression
More information2) Macrophages function to engulf and present antigen to other immune cells.
Immunology The immune system has specificity and memory. It specifically recognizes different antigens and has memory for these same antigens the next time they are encountered. The Cellular Components
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationANIMALS FORM & FUNCTION BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES. Animals Form & Function Activity #4 page 1
AP BIOLOGY ANIMALS FORM & FUNCTION ACTIVITY #4 NAME DATE HOUR BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES Animals Form & Function Activity #4 page 1 INFLAMMATORY RESPONSE ANTIMICROBIAL
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationMicrobiology AN INTRODUCTION EIGHTH EDITION
TORTORA FUNKE CASE Microbiology AN INTRODUCTION EIGHTH EDITION Differentiate between innate and acquired immunity. Chapter 17 Specific Defenses of the Host: The Immune Response B.E Pruitt & Jane J. Stein
More informationChapter 43: The Immune System
Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationName (print) Name (signature) Period. (Total 30 points)
AP Biology Worksheet Chapter 43 The Immune System Lambdin April 4, 2011 Due Date: Thurs. April 7, 2011 You may use the following: Text Notes Power point Internet One other person in class "On my honor,
More informationImmunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a
More informationEffectively Exploiting Big Data with Semantics
Effectively Exploiting Big Data with Semantics Thomas C. Rindflesch, Ph.D. National Library of Medicine, National Institutes of Health Digital Government Institute s Government Big Data Conference, October
More informationOncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder
Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research
More informationUnderstanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationImmunity and how vaccines work
1 Introduction Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non-adaptive) mechanisms
More informationNew strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
More informationCytotoxic and Biotherapies Credentialing Programme Module 2
Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal
More informationChapter 3. Immunity and how vaccines work
Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity
More informationUnderstanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
More informationImmuno-Oncology Therapies to Treat Lung Cancer
Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own
More informationB Cells and Antibodies
B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production
More informationAutoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
More informationThe Immune System and Disease
Chapter 40 The Immune System and Disease Section 40 1 Infectious Disease (pages 1029 1033) This section describes the causes of disease and explains how infectious diseases are transmitted Introduction
More informationMEDICAL BREAKTHROUGHS RESEARCH SUMMARY
MEDICAL BREAKTHROUGHS RESEARCH SUMMARY TOPIC: Training the Body to Fight Melanoma REPORT: 3823 BACKGROUND: Melanoma is the most dangerous form of skin cancer that can be hard to treat and fatal if not
More informationCancer and the immune system: can we beat cancer at its own game?
Cancer and the immune system: can we beat cancer at its own game? Andrew R. Haas, MD, PhD Assistant Professor of Medicine University of Pennsylvania Medical Center Philadelphia, Pa Why can t immune
More informationVeterinary Oncology: The Lumps We Hate To Treat
Veterinary Oncology: The Lumps We Hate To Treat Michelle Turek, DVM, DACVIM (Oncology), DACVR (Radiation Oncology) College of Veterinary Medicine University of Georgia Athens, GA Veterinary Oncology Veterinary
More informationYour Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer
Your Certified Professional Cancer Coach An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer The CPCC Patient Program Nutrition & Lifestyle Oncology A Cancer Diagnosis
More informationTransgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO
Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous
More informationCONTENT. Chapter 1 Review of Literature. List of figures. List of tables
Abstract Abbreviations List of figures CONTENT I-VI VII-VIII IX-XII List of tables XIII Chapter 1 Review of Literature 1. Vaccination against intracellular pathogens 1-34 1.1 Role of different immune responses
More informationCD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,
More informationSupplemental Material CBE Life Sciences Education. Su et al.
Supplemental Material CBE Life Sciences Education Su et al. APPENDIX Human Body's Immune System Test This test consists of 31 questions, with only 1 answer to be selected for each question. Please select
More informationBasics of Immunology
Basics of Immunology 2 Basics of Immunology What is the immune system? Biological mechanism for identifying and destroying pathogens within a larger organism. Pathogens: agents that cause disease Bacteria,
More informationGene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
More informationThe Body s Defenses CHAPTER 24
CHAPTER 24 The Body s Defenses PowerPoint Lectures for Essential Biology, Third Edition Neil Campbell, Jane Reece, and Eric Simon Essential Biology with Physiology, Second Edition Neil Campbell, Jane Reece,
More informationThe immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationBioMmune Technologies Inc. Corporate Presentation 2015
BioMmune Technologies Inc Corporate Presentation 2015 * Harnessing the body s own immune system to fight cancer & other autoimmune diseases BioMmune Technologies Inc. (IMU) ABOUT A public biopharmaceutical
More informationCancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center
Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationFulfilling the Promise
Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,
More informationThe Immune System. 2 Types of Defense Mechanisms. Lines of Defense. Line of Defense. Lines of Defense
The Immune System 2 Types of Defense Mechanisms Immune System the system that fights infection by producing cells to inactivate foreign substances to avoid infection and disease. Immunity the body s ability
More informationAn Introduction To Immunotherapy And The Promise Of Tissue Phenomics
An Introduction To Immunotherapy And The Promise Of Tissue Phenomics INSIDE: n The Potential of Immunotherapy n Towards an Understanding of Immunotherapy n Current Approaches to Immunotherapy n The Immunotherapy
More informationOne out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3
1. What is cancer? 2. What causes cancer?. What causes cancer? 3. Can cancer be prevented? The Facts One out of every two men and one out of every three women will have some type of cancer at some point
More informationCancer: DNA Synthesis, Mitosis, and Meiosis
Chapter 5 Cancer: DNA Synthesis, Mitosis, and Meiosis Copyright 2007 Pearson Copyright Prentice Hall, 2007 Inc. Pearson Prentice Hall, Inc. 1 What Is Cancer? Benign tumors do not invade surrounding tissue
More informationMutations: 2 general ways to alter DNA. Mutations. What is a mutation? Mutations are rare. Changes in a single DNA base. Change a single DNA base
Mutations Mutations: 2 general ways to alter DNA Change a single DNA base Or entire sections of DNA can move from one place to another What is a mutation? Any change in the nucleotide sequence of DNA Here
More informationCore Topic 2. The immune system and how vaccines work
Core Topic 2 The immune system and how vaccines work Learning outcome To be able to describe in outline the immune system and how vaccines work in individuals and populations Learning objectives Explain
More informationWhy use passive immunity?
Vaccines Active vs Passive Immunization Active is longer acting and makes memory and effector cells Passive is shorter acting, no memory and no effector cells Both can be obtained through natural processes:
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationInternational Symposium on Malignant Mesothelioma 2011 -- curemeso.org
Measles virotherapy for malignant mesothelioma Manish R. Patel, D.O. Assistant Professor of Medicine University of Minnesota June 25, 2011 Medical Treatment of Mesothelioma Majority of patients are not
More informationFederal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights
ADVANCED TE CHNOLOGY P ROGRAM The Advanced Technology Program Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights April 2006 National Institute of Standards and Technology
More informationCancer can occur at almost any organ in the body
Cancer can occur at almost any organ in the body There are many different types of cancers affecting different parts of the body. A cancer, or tumor, can occur in any organ or tissue of the human body.
More information10. T and B cells are types of a. endocrine cells. c. lymphocytes. b. platelets. d. complement cells.
Virus and Immune System Review Directions: Write your answers on a separate piece of paper. 1. Why does a cut in the skin threaten the body s nonspecific defenses against disease? a. If a cut bleeds, disease-fighting
More informationLevel 1. Nutrition & Lifestyle Oncology Certificate
Level 1 Nutrition & Lifestyle Oncology Certificate ONE MODULE 1 A Cancer Diagnosis Learn what cancer is; how/why it develops; diagnostic tests; inflammatory/ hormonal connections; 5 most important steps
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationCHAPTER 2: UNDERSTANDING CANCER
CHAPTER 2: UNDERSTANDING CANCER INTRODUCTION We are witnessing an era of great discovery in the field of cancer research. New insights into the causes and development of cancer are emerging. These discoveries
More informationRecognized causes of Cancer in dogs and Cats & Advances in Cancer treatment in Pet Animals
Recognized causes of Cancer in dogs and Cats & Advances in Cancer treatment in Pet Animals Dennis W, Macy DVM, MS, DACVIM Oncology and Internal Medicine Professor Emeritus, Colorado State University, Fort
More informationIMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER BOOKLET SUPPLEMENT Immunotherapy Immunotherapy is one of the most exciting new approaches for treating several types of cancer, including lung cancer. Immunotherapies
More informationUnderstanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org
Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS foundationforwomenscancer.org Contents Introduction...1 CA 125................................... 1 The CA 125 Test...2 The Use of the CA
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
More informationtargeted therapy a guide for the patient
targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting
More information1) Siderophores are bacterial proteins that compete with animal A) Antibodies. B) Red blood cells. C) Transferrin. D) White blood cells. E) Receptors.
Prof. Lester s BIOL 210 Practice Exam 4 (There is no answer key. Please do not email or ask me for answers.) Chapters 15, 16, 17, 19, HIV/AIDS, TB, Quorum Sensing 1) Siderophores are bacterial proteins
More informationAsthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System
1 2 3 4 5 6 7 8 9 Asthma (With a little SCID to start) Lauren Smith, MD CHKD Pediatric Allergy/Immunology Disclosures None Will be discussing some medications that are not yet FDA approved Outline SCID
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationBlood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide
Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood
More informationICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
More informationChapter 18: Applications of Immunology
Chapter 18: Applications of Immunology 1. Vaccinations 2. Monoclonal vs Polyclonal Ab 3. Diagnostic Immunology 1. Vaccinations What is Vaccination? A method of inducing artificial immunity by exposing
More informationEquity markets Major advances in cancer therapeutics 18 August 2015
Major advances in cancer therapeutics 18 August 2015 CIO WM Research Jerome Brimeyer, Equity Sector Strategist, jerome.brimeyer@ubs.com Our cancer therapeutics investment theme recommends companies that
More informationCancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview
Brochure More information from http://www.researchandmarkets.com/reports/3066973/ Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview Description:
More informationLYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis
LYMPHOMA IN DOGS Lymphoma is a relatively common cancer in dogs. It is a cancer of lymphocytes (a type of white blood cell) and lymphoid tissues. Lymphoid tissue is normally present in many places in the
More informationA Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
More informationHapten - a small molecule that is antigenic but not (by itself) immunogenic.
Chapter 3. Antigens Terminology: Antigen: Substances that can be recognized by the surface antibody (B cells) or by the TCR (T cells) when associated with MHC molecules Immunogenicity VS Antigenicity:
More informationThe Immune System: A Tutorial
The Immune System: A Tutorial Modeling and Simulation of Biological Systems 21-366B Shlomo Ta asan Images taken from http://rex.nci.nih.gov/behindthenews/uis/uisframe.htm http://copewithcytokines.de/ The
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationThe Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.
The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against
More informationPh.D. in Molecular Medicine
Ph.D. in Molecular Medicine and Translational Research College of Medicine 1. Introduction: The College of Medicine, while consolidating on its undergraduate innovative educational programs, decided to
More informationDrug treatments for kidney cancer
James Whale Fund for Kidney Cancer Drug treatments for kidney cancer Before your doctors can discuss treatment options with you they need to know how far your cancer has progressed. Staging is used to
More informationCanine Lymphoma Frequently Asked Questions by Pet Owners
Canine Lymphoma Frequently Asked Questions by Pet Owners What is lymphoma? The term lymphoma describes a diverse group of cancers in dogs that are derived from white blood cells called lymphocytes. Lymphocytes
More informationYour Immune System & Lung Cancer Treatment
Your Immune System & Lung Cancer Treatment Immunotherapy and Lung Cancer Immunotherapy is quickly developing as an important approach to treating many forms of cancer, including lung cancer. Immunotherapy
More informationAdjuvant Therapy for Breast Cancer: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
More informationNews Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Markus Talanow +49 6151 72 7144 Investor Relations +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor
More informationCancer Clinical trials:
Cancer Clinical trials: All you need to know A booklet for patients with cancer The future of cancer therapy F O R E W O R D If you have cancer, clinical trials may offer you additional treatment options.
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress Rescue Chemotherapy Protocols for Dogs with Lymphoma Kenneth M. Rassnick, DVM, DACVIM (Oncology) Cornell University
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 10 October 2007 Doc. Ref. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationAchievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for
Achievements Report August 2015 CURING CANCER Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for cancer? Since cancer is complex and comes in many forms, its
More informationPRINIPLES OF RADIATION THERAPY Adarsh Kumar. The basis of radiation therapy revolve around the principle that ionizing radiations kill cells
PRINIPLES OF RADIATION THERAPY Adarsh Kumar The basis of radiation therapy revolve around the principle that ionizing radiations kill cells Radiotherapy terminology: a. Radiosensitivity: refers to susceptibility
More informationFuture strategies for myeloma: An overview of novel treatments In development
Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide
More informationThe Biological Basis of Cancer. Annie Young, Professor of Nursing, University of Warwick, University Hospitals Coventry and Warwickshire
The Biological Basis of Cancer Annie Young, Professor of Nursing, University of Warwick, University Hospitals Coventry and Warwickshire Aim of Presentation By the end of this presentation you will: Be
More informationActivation and effector functions of HMI
Activation and effector functions of HMI Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 25 August 2015 ว ตถ ประสงค หล งจากช วโมงบรรยายน แล วน กศ กษาสามารถ
More informationYour Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
More informationLESSON 3.5 WORKBOOK. How do cancer cells evolve? Workbook Lesson 3.5
LESSON 3.5 WORKBOOK How do cancer cells evolve? In this unit we have learned how normal cells can be transformed so that they stop behaving as part of a tissue community and become unresponsive to regulation.
More informationSommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
More informationCHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS
CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS See APPENDIX (1) THE PRECIPITIN CURVE; (2) LABELING OF ANTIBODIES The defining characteristic of HUMORAL immune responses (which distinguishes them from CELL-MEDIATED
More informationFoundational Issues Related to Immunotherapy and Melanoma
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More information